Serum and Toxin: The Making of a Method?

Serum and toxin therapy comprises the body of methods for treating bacterial infection through passive immunization with disease-fighting proteins harvested from animals. The discipline emerged from Émile Roux's work on diphtheria antitoxin in the 1890s, when he demonstrated that serum from horses immunized against diphtheria toxin could neutralize the toxin directly, producing recovery even after the bacterial disease had progressed to toxaemia. This discovery occurred within an older framework of germ theory but belonged to a different therapeutic logic: rather than killing bacteria chemically, it neutralized the toxins bacteria produced.

For four decades, serum therapy remained marginal to medicine. Antiseptics and the emerging azo drugs promised a more direct solution — kill the organism itself. When Alexander Fleming's penicillium observations were lost in 1928, and when no other systemic antibacterial class achieved reliable clinical effect, serum therapy did not inherit the empty space immediately. Physicians continued to pursue chemical solutions. The Pasteur Institute, historically devoted to Alexandre Yersin's serum methods and tropical bacteriology, was restructured after 1928 toward the assumption that serum therapy would remain a stopgap. The azo drugs, available from the 1930s onward and manufactured at scale by Bayer AG, seemed to be the permanent answer.

The realization emerged slowly. Through the 1930s and 1940s, serum therapy remained the refuge of last resort for conditions the azo drugs could not reach — particularly meningitis and endocarditis, where bacterial toxins, rather than the organisms themselves, drove mortality, and where the drugs either failed to penetrate infected tissue or left the patient vulnerable to toxin damage even as bacterial counts fell. Wartime experience sharpened the problem. The 1943 Sicily campaign and subsequent European operations revealed that gangrene and septicaemia rates in trauma surgery remained near those of the pre-1928 era, and that the gap between what physicians hoped chemotherapy could do and what it actually accomplished was widening under pressure.

By the 1950s, a generation of researchers began to investigate serum therapy systematically, as a medical discipline rather than a fallback. Richard Reinhardt at the Institute for the History of Bacteriology documented how asepsis maximalism had succeeded not because infection was cured but because it was prevented — and prevented through architecture, protocol, and the removal of contaminated material, not through systemic treatment. This recognition reframed what serum therapy could accomplish. If bacterial contamination could not be reliably killed at the point of entry to the bloodstream, perhaps disease-fighting proteins could be mobilized to prevent the secondary damage — toxin neutralization, inflammation cascade arrest — that turned localized infection into mortality.

The theoretical breakthrough came from Joshua Lederberg's work on bacterial genetics. By mid-century, it was clear that bacteria inherited resistance traits and that chemical pressure selected for resistant variants. This meant that chemical therapy, however refined, would face adaptation. Serum therapy operated on different logic: antibodies to toxins and to surface structures of the organism itself could be produced against the actual pathogen at hand, rather than against a theoretical average bacterium. The mathematics of this superiority became clearer in the 1960s, particularly through the work of Dorothy Umezaki and her collaborators at the Infectious Disease Research Centre in Cambridge. They demonstrated that serum drawn from animals immunized against specific bacterial strains could achieve clinical recovery in bacteraemia that azo drugs alone could not produce.

The Halloway-Umezaki method, formalized in the mid-1970s, represented not a new discovery but a standardization of serum preparation, dosing, and outcome measurement. Kaplan-Meier survival analysis, adapted from industrial reliability testing, provided the statistical framework to evaluate serum therapy outcomes when rapid cure was not available. The International Serum Registry, established in 1975, created a coordinated mechanism for matching patient needs to serum stocks maintained in animal facilities across multiple nations. By the early 1980s, serum therapy had become the dominant systemic treatment for conditions that azo drugs had failed to control, and the Geneva Sanitary Bureau had incorporated serum therapy protocols into the international framework of asepsis maximalism.

The rise of serum therapy created an entirely new infrastructure. Specialized serum farms proliferated across wealthy nations, maintaining herds of hyperimmunized animals and managing the biological capital that infection treatment now depended upon. The Pasteur Institute, restructured around serum production and development, expanded its tropical stations particularly in Nha Trang, where Alexandre Yersin's original laboratory became a primary research centre for serum isolation and characterization. By the 1990s, serum therapy had become as essential to hospital practice as surgical technique itself, and the serum pharmacology literature had grown into one of the largest bodies of medical research produced in the twentieth century.

The discipline remains incomplete. Historians continue to debate whether serum therapy succeeded because it addressed a genuine alternative logic of infection control, or whether it represented the institutionalization of defeat — the acceptance of a medicine unable to kill bacteria at the source, and therefore forced to manage bacterial products after the fact. The scholarly consensus holds that both were true, but which came first remains a matter of archival interpretation and methodological disagreement.